AKT1 and neoplasm: Antitumour drugs should ideally counteract the abnormal apoptosis, invasion and migration of malignant tumor cells [26], and these conditions are often related to abnormal protein expression, increased oxidative stress or abnormal activity of signaling pathways, such as the MAPK/Erk [27], NF-κB [28] and PI3K/Akt [15] pathways.